DDInter485 DDInter596
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) upregulates {v} (Gene) NDUFS7
NDUFS7 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) upregulates {v} (Gene) P4HA2
P4HA2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Anthracyclines
Anthracyclines {u} (Pharmacologic Class) includes {v} (Compound) Doxorubicin
Daunorubicin {u} (Compound) downregulates {v} (Gene) TSKU
TSKU {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Daunorubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) resembles Epirubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Daunorubicin (Compound) upregulates NDUFS7 (Gene) and NDUFS7 (Gene) is bound by Doxorubicin (Compound)
Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Daunorubicin (Compound) upregulates P4HA2 (Gene) and P4HA2 (Gene) is upregulated by Doxorubicin (Compound)
Daunorubicin (Compound) is included by Anthracyclines (Pharmacologic Class) and Anthracyclines (Pharmacologic Class) includes Doxorubicin (Compound)
Daunorubicin (Compound) downregulates TSKU (Gene) and TSKU (Gene) is downregulated by Doxorubicin (Compound)